Начало・Списък с акции・Ovid therapeutics Inc

Ovid therapeutics Inc

Затворен

СекторЗдравеопазване

2.82 1.81

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.59

Максимум

2.86

Ключови измерители
By Trading Economics
Приходи	-27M -17M
EPS	-0.12
Марж на печалбата	-2,366.017
Служители	23
EBITDA	-4.7M -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+138.55% upside

Дивиденти
By Acuity
Следващи печалби	11.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6.2M 489M
Предишно отваряне	1.01
Предишно затваряне	2.82

Настроения в новините

By Acuity

41%

59%

141 / 340 Класиране в Healthcare

Ovid therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.08.2026 г., 19:16 ч. UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12.08.2026 г., 19:46 ч. UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7.08.2026 г., 19:26 ч. UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6.08.2026 г., 22:51 ч. UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5.08.2026 г., 21:03 ч. UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4.08.2026 г., 23:01 ч. UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3.08.2026 г., 19:11 ч. UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31.07.2026 г., 20:02 ч. UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27.07.2026 г., 20:07 ч. UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22.07.2026 г., 18:46 ч. UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20.07.2026 г., 19:36 ч. UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Сравнение с други в отрасъла

Ценова промяна

Ovid therapeutics Inc Прогноза

Ценова цел

By TipRanks

138.55% нагоре

12-месечна прогноза

Среден 6.25 USD 138.55%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Ovid therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Ovid therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

141 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.